Mesenchymal Stem Cells Ameliorate Sepsis-associated Acute Kidney Injury in Mice

Abstract

Treatment with MSCs can alleviate sepsis-associated AKI and improve survival in mice with polymicrobial sepsis. These effects may be mediated by the inhibition of IL-17 secretion and balance of the proinflammatory and anti-inflammatory states. Mesenchymal stem cells may be a potential new therapeutic agent for the prevention or reduction of sepsis-associated AKI.

Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis

“…40 Intravenous MSCs improve lung histology and decrease concentrations of proinfl ammatory cytokines in BAL fl uid after infection, 28,38 decrease concentrations of infl ammatory cytokines in cardiac tissue and improve cardiac function after intravenous LPS, 36 and also lower renal expression of proinfl ammatory cytokines and improve serological markers of kidney function after caecal ligation and puncture. 37 These eff ects occurred without substantial MSC localisation to the studied tissue, which suggests a paracrine mechanism. As with lung injury models, investigators have used infection models to identify paracrine factors that might contribute to the observed benefi ts of MSCs.…”

“…37,38,[48][49][50][51] This antibacterial eff ect is partly mediated by improved phagocytic activity of host immune cells such as macrophages, 38,41 monocytes, 48 neutrophils, 49 and ITGAMpositive cells (monocytes, macrophages, and neutrophils). 38 Studies using ex-vivo human lungs have reported similar fi ndings.…”

The Beneficial Effects of Agomelatine in Experimental Model of Sepsis Related Acute Kidney Injury

“…The authors suggested that the inflammation largely contributed to the pathogenesis of AKI. [30] Similarly, Chancharoenthana and et al demonstrated that hypercytokinemia plays a more distinct role in sepsis-related AKI than in non-sepsis related AKI. [31] It has been determined that oxidative stress plays an important role in sepsis-related AKI.…”

Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva

“…Como placebo se utilizó una inyección de fibroblastos, suero salino o MSC inactivados por shock térmico. El tratamiento de soporte consistió en antibióticos y volumen, los que fueron administrados a los grupos experimental y placebo [24][25][26][27][28][29] . El momento de la infusión y la dosis de MSCs fue variable entre los estudios.…”